BioCardia, Inc.
BCDA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000925741
In the last 90 days, BioCardia, Inc. insiders filed 10 open-market purchases and 0 sales; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding BioCardia, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 16 | 24 | +8 |
| Shares | 1.65M | 2.06M | +404.1K (+24.4%) |
| Value | $709.6K | $1.37M | +$655.7K (+92.4%) |
New holders (8)
Institutions that held BioCardia, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 65,426 | $43.5K | 0.00% |
| Virtu Financial LLC | 41,348 | $27.0K | 0.00% |
| Citadel Advisors LLC | 33,629 | $22.3K | 0.00% |
| Scientech Research LLC | 23,032 | $14.9K | 0.01% |
| Pingora Partners LLC | 7,417 | $4.93K | 0.00% |
| Global Retirement Partners, LLC | 6,177 | $3.83K | 0.00% |
| Tower Research Capital LLC (TRC) | 240 | $159 | 0.00% |
| Royal Bank of Canada | 223 | $0 | 0.00% |
Sold out (0)
Institutions that held BioCardia, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
None.